ArticleTranslational cancer research2025
Integrative single-cell and bulk transcriptomes analyses reveal T cell-related prognostic risk model and tumor immune microenvironment modulation in colorectal cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is among the most common and lethal cancers worldwide. Recent advances in tumor immunotherapy have highlighted the importance of T-cell subsets and the tumor microenvironment (TME) in CRC, both critical for mounting a successful anti-tumor immune response. Thus, there is an urgent need for comprehensive research in these areas to accelerate the development of personalized immunotherapeutic strategies for CRC patients. Therefore, this study aims to explore T-cell heterogeneity, identify characteristic genes, and develop a reliable prognostic model to predict patient outcomes and immunotherapy responses. Methods: CRC single-cell RNA sequencing (scRNA-seq) data were downloaded from the Gene Expression Omnibus (GEO) database. We identified T cell feature genes and employed Cox and least absolute shrinkage and selection operator (LASSO) regression methods to construct a prognostic model using The Cancer Genome Atlas (TCGA) dataset, while GEO dataset was utilized for validation. Additionally, we analyzed the immune microenvironment, immune checkpoints, and drug sensitivity between the high-risk and low-risk groups. Results: Based on scRNA-seq data, we identified 4,440 T cell marker genes. There were also interactions between T cells and various other cell types. The results of the enrichment analysis revealed that these marker genes were primarily involved in immune-related pathways. After conducting univariate Cox and LASSO analyses, we developed a prognostic model based on the expression levels of three prognostic genes: Conclusions: This study discovered three key genes with prognostic relevance in CRC, providing valuable insights into T-cell heterogeneity and the associated prognostic risk model. The results demonstrated that this model accurately predicts patient prognosis and responses to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.